The medical device maker raised its full-year sales guidance to $6.6B-$6.9B following stronger-than-expected quarterly results.
Edwards Lifesciences raised its 2026 revenue forecast to $6.6 billion-$6.9 billion after reporting second-quarter earnings that exceeded expectations. The company previously guided to $6.5 billion-$6.9 billion, with consensus estimates at $6.74 billion.
The updated outlook reflects stronger performance in its core businesses, including transcatheter heart valves and critical care products. Shares rose approximately 7% in after-hours trading following the announcement.
Analysts noted the guidance revision signals confidence in sustained demand for the company’s medical technologies amid a recovering procedural volume environment.